Anti-Brain Tumor Peptide Vaccines for Brain Tumors

Due to the presence of specific proteins on the surface of tumor cells, brain tumor vaccines can target these proteins by targeting them, and then the immune system can specifically eliminate the tumor cells without harming normal cells. Preventive and therapeutic vaccines against brain tumors have been introduced as new weapons that can stop the progression of the disease, prevent a recurrence, and even help humans beat brain tumors as a treatment.

Our anti-brain tumor peptide vaccines development services

Alfa Cytology offers peptide vaccine development services for the treatment and prevention of brain tumors, especially for the prevention of brain tumor metastasis, and also offers pharmaceutical compositions comprising peptide vaccines. Among them, peptide vaccines contain peptide fragments of intracellular cancer proteins. Peptide vaccines comprise about 8-30 amino acids. Their structural design includes either TSA (tumor-specific antigen) or TAA (tumor-associated antigen.) TSA is derived from mutants expressed by tumor cells and not from normal cells, while TAA is derived from the overexpression of normal proteins in tumor cells and normal cells. Unlike other solid tumors, some brain tumors, such as glioblastoma (GBM), have relatively low levels of mutations, and therefore only a few TSAs can be used in the structural design of anti-brain tumor peptide vaccines.

Novel GBM-specific therapeutic vaccines containing multiple tumor-associated peptides.

The single-target vaccines designed for GBM involve targets such as EGFRvIII, survivin, and IDH. Survivin is an anti-apoptotic protein that is highly expressed in a variety of malignancies, including 95% of gliomas. Vaccines targeting survivin protein can activate both T cell and B cell immunity, as well as antibody-mediated survivin pathway inhibition, thus exerting both cell- and antibody-mediated anti-tumor effects. By activating the immune system to kill survivin-positive tumor cells, it stops tumor proliferation and acts to prevent or delay tumor recurrence.

Peptide vaccine therapeutic flow

• Providing applications for vaccine therapy, including intracellular oncoprotein fragments for vaccination to stimulate the host to produce its antibodies to prevent tumor formation.
• Providing a polypeptide for use in a method of stimulating the production of antibodies against an intracellular oncoprotein in a subject in need thereof. The polypeptide is a fragment of an intracellular oncoprotein having from 10 to 150 amino acids, preferably from 10 to 100 amino acids.
• Providing a method for stimulating the production of an anti-internal cellular oncoprotein antibody in a subject in need thereof comprising giving a polypeptide which is a fragment of an intracellular oncoprotein having from 10 to 150 amino acids.

Mutations in the brain tumor genome often lead to changes in proteins typically found in tumors, and vaccines can alert the patient's immune system to these mutated proteins. Alfa Cytology' peptide vaccine development program for brain tumors includes single-target vaccines, multi-target combination vaccines, and individualized vaccines. Please feel free to contact us to initiate your peptide vaccine development program.